COVID-19 Frequently Asked Questions (FAQs)
If the answer to your question is not located here or in one of the following resources, please submit it through Health Center Program Support online 
and select "Coronavirus Inquiries (COVID-19)" as the issue type, or call 877-464-4772, option 2, 8 a.m. to 8 p.m. ET, Monday-Friday (except federal holidays).
Access more COVID-19 Information for Health Centers and Partners.
Access resources for UDS Novel Coronavirus Disease (COVID-19) Reporting.
Access additional frequently asked questions on:
- COVID-19 (H8C), CARES Act (H8D), and Expanding Capacity for Coronavirus Testing (ECT) (H8E) funding for health centers
- American Rescue Plan funding for health centers (H8F)
- American Rescue Plan – Health Center Construction and Capital Improvements (C8E)
- American Rescue Plan – Funding for Native Hawaiian Health Care (H2C)
- American Rescue Plan funding for state and regional Primary Care Associations (U5F)
- American Rescue Plan funding for National Training and Technical Assistance Partners (U3F)
- American Rescue Plan funding for Health Center Controlled Networks (HQC)
- Health Center Program Look-Alikes: Expanding Capacity for Coronavirus Testing (LAL ECT) funding (L1C)
- American Rescue Plan – Funding for Look-Alikes (ARP-LAL) (L2C)
Health Center COVID-19 Therapeutics Program
The HRSA Health Center COVID-19 Therapeutics Program provides health centers with a direct allocation of oral antiviral medications (therapeutics) for the outpatient treatment of mild to moderate COVID-19. In order to ensure equitable access among the nation’s underserved communities and those disproportionately affected by COVID-19 and in support of the Biden-Harris Administration’s Test to Treat Initiative, this program provides an additional supply of oral antiviral pills directly to HRSA-supported health centers, supplementing state/jurisdictional allocations.
The HRSA Health Center COVID-19 Therapeutics Program began incrementally in December 2021 at approximately 200 health centers. These initial participants were selected because they have pharmacy capacity and specialize in caring for particularly underserved and disproportionately affected populations (for example, a significant number of people experiencing homelessness, migratory/seasonal agricultural workers, residents of public housing, people 65 or older, and those with limited English proficiency), or have reported significant COVID-19 testing activity in the biweekly Health Center COVID-19 Survey.
On March 7, 2022, the program expanded its reach by doubling the number of invited health centers to over 400, and on March 28, 2022, the program became open to all health centers and Health Center Program look-alikes with pharmacy capacity.
(Updated: 3/29/2022)
Yes, the program became open to Health Center Program look-alikes with pharmacy capacity, in addition to all HRSA-funded health centers with pharmacy capacity, on March 28, 2022.
(Updated: 3/29/2022)
Yes, health centers may order oral antiviral medications (therapeutics) through separate allocations from their state/jurisdiction. The HRSA Health Center COVID-19 Therapeutics Program allocation is not meant to replace participating health centers’ current state allocations. The program supplements state/jurisdictional COVID-19 therapeutics allocations to ensure equitable access by providing an additional supply directly to populations served by HRSA-supported health centers.
(Updated: 3/29/2022)
To identify participating health centers and coordinate the distribution of therapeutics, states may contact the HHS Office of the Assistant Secretary for Preparedness and Response at COVID19.Therapeutics@hhs.gov.
(Added: 1/21/2022)
Health centers must dispense therapeutics in accordance with the FDA’s Emergency Use Authorization (EUA) conditions of use and in accordance with federal clinical guidance. Please visit the NIH COVID-19 Treatment Guidelines for up-to-date, evidence-based recommendations on the management of COVID-19. In addition to the relevant FDA and NIH guidance, please follow all applicable state, local, or health center policies and guidelines.
(Added: 1/21/2022)
- Outpatient Therapeutics Decision Guide for Providers
- NIH COVID-19 Treatment Guidelines
- COVID-19 Treatment Guidelines Panel’s Interim Statement on Patient Prioritization for Outpatient Anti-SARS-CoV-2 Therapies or Preventive Strategies When There Are Logistical or Supply Constraints
- FDA EUA news release for Merck’s Molnupiravir, including fact sheets, letter of authorization, and FAQs
- FDA EUA news release for Pfizer’s Paxlovid, including fact sheets, letter of authorization, and FAQs
(Added: 1/21/2022)
Contact Us
- Subscribe to weekly BPHC updates
- HRSA News & Events
- Key BPHC Staff
- Health Center Program Support or call 877-464-4772. 8 a.m. to 8 p.m. ET, Monday - Friday (except federal holidays)
